Several anti-ErbB3 monoclonal antibodies are under development and have been brought to clinical trials for a variety of indications such as breast, colorectal and ovarian cancers, given the known role of ErbB3 in resistance to therapy [30, 51, 52]. This evidence concerns the gene ERBB3 and ovarian cancer.